KR102646702B1 - 항암제 및 그의 제조 - Google Patents
항암제 및 그의 제조 Download PDFInfo
- Publication number
- KR102646702B1 KR102646702B1 KR1020197011144A KR20197011144A KR102646702B1 KR 102646702 B1 KR102646702 B1 KR 102646702B1 KR 1020197011144 A KR1020197011144 A KR 1020197011144A KR 20197011144 A KR20197011144 A KR 20197011144A KR 102646702 B1 KR102646702 B1 KR 102646702B1
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- group
- cancer
- compound
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662398783P | 2016-09-23 | 2016-09-23 | |
| US62/398,783 | 2016-09-23 | ||
| PCT/US2017/052967 WO2018057897A1 (en) | 2016-09-23 | 2017-09-22 | Anti-cancer agents and preparation thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190077340A KR20190077340A (ko) | 2019-07-03 |
| KR102646702B1 true KR102646702B1 (ko) | 2024-03-11 |
Family
ID=61690726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197011144A Active KR102646702B1 (ko) | 2016-09-23 | 2017-09-22 | 항암제 및 그의 제조 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10858371B2 (https=) |
| EP (1) | EP3515492B1 (https=) |
| JP (1) | JP7111722B2 (https=) |
| KR (1) | KR102646702B1 (https=) |
| CN (1) | CN109862916A (https=) |
| AU (1) | AU2017331260B2 (https=) |
| BR (1) | BR112019005885A2 (https=) |
| CA (1) | CA3037883A1 (https=) |
| DK (1) | DK3515492T3 (https=) |
| IL (1) | IL265521B2 (https=) |
| MA (1) | MA46291A (https=) |
| MX (1) | MX394670B (https=) |
| RU (1) | RU2019111768A (https=) |
| WO (1) | WO2018057897A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7111722B2 (ja) | 2016-09-23 | 2022-08-02 | パーデュー・リサーチ・ファウンデーション | 抗がん剤およびその調製方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901464A (fr) | 1943-01-23 | 1945-07-27 | Boehringer & Soehne Gmbh | Procédé d'obtention de vanilline |
| US7825267B2 (en) | 2006-09-08 | 2010-11-02 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Synthesis of FR901464 and analogs with antitumor activity |
| WO2009031999A1 (en) | 2007-09-07 | 2009-03-12 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Fr901464 and analogs with antitumor activity and method for their preparation |
| CN101417934B (zh) * | 2007-10-24 | 2012-04-18 | 国鼎生物科技股份有限公司 | 分离自牛樟芝萃取物的化合物 |
| NZ602675A (en) | 2008-03-18 | 2014-03-28 | Genentech Inc | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
| US8969405B2 (en) * | 2008-06-21 | 2015-03-03 | St. Jude Children's Research Hospital | Anticancer compounds and methods of making and using same |
| WO2013130882A1 (en) | 2012-02-28 | 2013-09-06 | Fred Hutchinson Cancer Research Center | Compositions and methods for treating cancer |
| MX340090B (es) * | 2012-11-05 | 2016-06-23 | Pfizer | Analogos de spliceostatina. |
| WO2014100367A1 (en) | 2012-12-21 | 2014-06-26 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Synthesis of fr901464 and analogs with antitumor activity |
| US20140274979A1 (en) | 2013-03-13 | 2014-09-18 | Golden Biotechnology Corporation | Method for the treatment of fatty liver disease |
| ES2955206T3 (es) | 2013-07-15 | 2023-11-29 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh | Derivados de espiroquinoxalina como inhibidores de la muerte celular regulada no apoptótica |
| KR102092569B1 (ko) * | 2013-09-17 | 2020-03-25 | 엘지디스플레이 주식회사 | 터치 스크린 일체형 디스플레이 장치와 이의 구동 방법 |
| CN113461705A (zh) * | 2013-11-19 | 2021-10-01 | 普渡研究基金会 | 抗癌剂及其制备 |
| AU2017277786A1 (en) * | 2016-06-08 | 2019-01-03 | William Marsh Rice University | Derivatives of Thailanstatin A, methods of treatment and methods of synthesis thereof |
| JP7111722B2 (ja) | 2016-09-23 | 2022-08-02 | パーデュー・リサーチ・ファウンデーション | 抗がん剤およびその調製方法 |
-
2017
- 2017-09-22 JP JP2019537750A patent/JP7111722B2/ja active Active
- 2017-09-22 KR KR1020197011144A patent/KR102646702B1/ko active Active
- 2017-09-22 US US16/335,378 patent/US10858371B2/en active Active
- 2017-09-22 IL IL265521A patent/IL265521B2/en unknown
- 2017-09-22 CA CA3037883A patent/CA3037883A1/en active Pending
- 2017-09-22 CN CN201780065546.7A patent/CN109862916A/zh active Pending
- 2017-09-22 AU AU2017331260A patent/AU2017331260B2/en active Active
- 2017-09-22 MA MA046291A patent/MA46291A/fr unknown
- 2017-09-22 MX MX2019003368A patent/MX394670B/es unknown
- 2017-09-22 DK DK17853991.2T patent/DK3515492T3/da active
- 2017-09-22 EP EP17853991.2A patent/EP3515492B1/en active Active
- 2017-09-22 WO PCT/US2017/052967 patent/WO2018057897A1/en not_active Ceased
- 2017-09-22 BR BR112019005885-0A patent/BR112019005885A2/pt unknown
- 2017-09-22 RU RU2019111768A patent/RU2019111768A/ru unknown
-
2020
- 2020-11-09 US US17/092,829 patent/US11851441B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL265521A (en) | 2019-05-30 |
| JP2019529563A (ja) | 2019-10-17 |
| EP3515492A1 (en) | 2019-07-31 |
| DK3515492T3 (da) | 2023-08-28 |
| US20210395265A1 (en) | 2021-12-23 |
| JP7111722B2 (ja) | 2022-08-02 |
| KR20190077340A (ko) | 2019-07-03 |
| US10858371B2 (en) | 2020-12-08 |
| AU2017331260A1 (en) | 2019-05-16 |
| MX2019003368A (es) | 2019-09-16 |
| EP3515492A4 (en) | 2020-04-08 |
| US20190218228A1 (en) | 2019-07-18 |
| MX394670B (es) | 2025-03-11 |
| US11851441B2 (en) | 2023-12-26 |
| EP3515492B1 (en) | 2023-07-26 |
| WO2018057897A1 (en) | 2018-03-29 |
| AU2017331260B2 (en) | 2024-11-07 |
| IL265521B2 (en) | 2024-09-01 |
| RU2019111768A (ru) | 2020-10-23 |
| IL265521B1 (en) | 2024-05-01 |
| MA46291A (fr) | 2019-07-31 |
| CN109862916A (zh) | 2019-06-07 |
| BR112019005885A2 (pt) | 2020-06-02 |
| CA3037883A1 (en) | 2018-03-29 |
| RU2019111768A3 (https=) | 2020-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6929903B2 (ja) | 抗癌剤およびその調製方法 | |
| US9670225B2 (en) | HIV-1 protease inhibitors and uses thereof | |
| JP2024164181A (ja) | カリスポンジオリド、その類似体、およびそれらの使用 | |
| TWI754676B (zh) | 苔蘚蟲素化合物及其製備方法 | |
| JPH08337584A (ja) | 縮合六環式アミノ化合物、これを含有する医薬及びその製法 | |
| US9828405B2 (en) | Morpholinyl anthracycline derivatives | |
| KR102646702B1 (ko) | 항암제 및 그의 제조 | |
| US11028096B2 (en) | Tricyclic P2-ligand containing potent HIV-protease inhibitors against HIV/AIDS | |
| HK40006497A (en) | Anti-cancer agents and preparation thereof | |
| WO2025007026A1 (en) | Heterobifunctional compounds and methods of use thereof | |
| HK1227866A1 (en) | Anti-cancer agents and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| AMND | Amendment | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| AMND | Amendment | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| AMND | Amendment | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PX0901 | Re-examination |
St.27 status event code: A-2-3-E10-E12-rex-PX0901 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| AMND | Amendment | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PX0701 | Decision of registration after re-examination |
St.27 status event code: A-3-4-F10-F13-rex-PX0701 |
|
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |